Agios Pharmaceuticals, Inc.
mitapivat
sickle cell disease
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for mitapivat in sickle cell disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Topline results from the RISE UP Phase 3 trial of mitapivat in sickle cell disease were reported in November 2025.”